#USA #Irvine #PeproMene Bio #PMB-CT01 #EHA 2026

PeproMene Bio Announces Presentation at EHA 2026

PeproMene Bio, Inc., a pioneering biotech firm based in Irvine, California, has announced that it will present updated clinical data on its investigational CAR-T therapy PMB-CT01 at the European Hematology Association's (EHA) 2026 conference. This presentation will showcase results from the ongoing Phase 1 study of PMB-CT01, which is designed to target the B-cell activating factor receptor (BAFF-R) in patients with B-cell lymphomas who have shown resistance or relapse after treatment with existing therapies, including CD19-targeted CAR-T therapy.

Key Findings from the Phase 1 Study

The data to be presented at EHA 2026 stem from the completed dose-escalation phase of the study involving patients diagnosed with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL). Among the nine patients enrolled in this phase, PMB-CT01 demonstrated a promising safety profile, exhibiting no dose-limiting toxicities, and no cases of cytokine release syndrome (CRS) greater than grade 1. Additionally, instances of immune effector cell-associated neurotoxicity syndrome (ICANS) were also not greater than grade 1.

Most notably, seven out of nine patients, representing 78%, achieved complete responses (CRs) to the treatment. Importantly, at the time of the last data cutoff, no relapses were reported, and all patients who achieved a response continued to maintain it. The longest duration of response exceeded three years, with these patients reaching a minimal residual disease (MRD)-negative status, indicating that there were no detectable remaining cancer cells.

These outcomes are particularly vital considering the significant unmet medical need that exists for patients experiencing cancer progression after traditional therapies, like CD19 CAR-T treatments.

Expansion Cohorts and Promising Developments

Based on the encouraging results, the study is currently enrolling patients for expansion cohorts targeting mantle cell lymphoma, large B-cell lymphoma, and follicular lymphoma. Notably, the initial patient treated in this expansion phase, who had a transformed follicular lymphoma (tFL)—an aggressive subtype with few effective treatment options—achieved a complete response at the first assessment following treatment with PMB-CT01.

Dr. Larry W. Kwak, the scientific founder of PeproMene Bio, remarked on the significance of these findings, stating, "When a cancer progresses following CD19 CAR-T therapy, there is a considerable unmet medical need due to the limited treatment options available at that point. These enduring complete responses underscore the clinical relevance of BAFF-R as a novel target, while the favorable safety profile observed thus far opens avenues for future applications in outpatient oncology settings and warrants further exploration in refractory autoimmune diseases."

Presentation Details at EHA 2026

• - Abstract Title: Durable Responses and Favorable Safety Profile of BAFF-R CAR-T Cells (PMB-CT01) in Patients with Relapsed/Refractory B-cell Lymphomas Following Previous CD19-Directed Therapy Failure or with CD19-Negative Disease
• - Abstract ID: EHA-1611 S287
• - Date & Time: June 14, from 11:00 to 12:15 CEST
• - Presenter: Dr. Larry W. Kwak, M.D., Ph.D.

About PMB-CT01

PMB-CT01 is an innovative, autologous first-in-class CAR-T therapy that specifically targets BAFF-R and is currently being evaluated in ongoing Phase 1 studies for relapsed/refractory B-NHL and B-cell acute lymphoblastic leukemia (B-ALL). BAFF-R is predominantly expressed on B cells and is critical for their survival, reducing the likelihood of escape through antigen loss.

About PeproMene Bio, Inc.

Founded to develop groundbreaking therapies for cancer and immune disorders, PeproMene Bio, Inc. operates at the forefront of biopharmaceutical innovation. For more information about the company and its initiatives, contact Dr. Hazel Cheng at email protected] or visit [pepromenebio.com.

Please note that this press release contains forward-looking statements, which involve risks and uncertainties related to clinical development, regulatory decisions, therapeutic potentials, and marketability. PeproMene Bio, Inc. disclaims any obligation to update forward-looking statements except as legally required.